Zhitong Finance App News, Chengyi Pharmaceutical (603811.SH) issued an announcement. Recently, the company's subsidiary Fujian Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as “Fujian Huakang”) obtained the drug's GMP compliance test results (number: FJSC2026-038) from the Fujian Drug Administration website. The production and quality management of the company's API glucosamine hydrochloride (added a production line for glucosamine hydrochloride in the B09 workshop) complies with the requirements of the “Pharmaceutical Production Quality Management Code (2010 Revision)” and its appendix.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.